Codeine
- Generic Name
- Codeine
- Brand Names
- Ascomp, Cheratussin, Cheratussin Dac, Codar Ar, Codar D, Codar Gf, Codeine Contin, Covan, Damylin With Codeine, Fioricet With Codeine, Histex Ac, Linctus Codeine Blanc, M-clear Wc, M-end PE, Mar-cof BP, Mar-cof Cg, Mersyndol, Ninjacof Xg, Pseudodine C, Robaxacet-8, Robaxisal, Triacin-C, Trianal C, Triatec, Triatec-30, Triatec-8, Tusnel C, Tuxarin, Tuzistra, Tylenol With Codeine
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21NO3
- CAS Number
- 76-57-3
- Unique Ingredient Identifier
- UX6OWY2V7J
- Background
The relief of pain (analgesia) is a primary goal for enhancing the quality of life of patients and for increasing the ability of patients to engage in day to day activities. Codeine, an opioid analgesic, was originally approved in the US in 1950 and is a drug used to decrease pain by increasing the threshold for pain without impairing consciousness or altering other sensory functions. Opiates such as codeine are derived from the poppy plant, Papaver somniferum (Papaveraceae).
Codeine is utilized as a central analgesic, sedative, hypnotic, antinociceptive, and antiperistaltic agent, and is also recommended in certain diseases with incessant coughing.
- Indication
Codeine sulfate is a form of this drug that is commonly used. It is available in tablet form and indicated for the relief of mild to moderately severe pain, where the use of an opioid analgesic is appropriate .
The solution form is used by itself or combined in a syrup with other drugs and is used as a cough suppressant in adults aged 18 and above , .
- Associated Conditions
- Common Cold, Cough, Flu caused by Influenza, Mild pain, Pain, Severe Pain, Dry cough, Moderate Pain, Upper respiratory symptoms
- Associated Therapies
- Airway secretion clearance therapy
Effect of Methylnaltrexone on GI Transit in Healthy Volunteers
- Conditions
- Gastric Motility Disorder
- Interventions
- Drug: Placebo + placebo
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2012-06-25
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 48
- Registration Number
- NCT01055704
- Locations
- 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States
Dose Linearity Study of Codeine Sulfate Under Fasted Conditions
- Conditions
- Pain
- First Posted Date
- 2009-11-09
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 34
- Registration Number
- NCT01009697
- Locations
- 🇺🇸
CEDRA Clinical Research, Austin, Texas, United States
Food Effect Study of Codeine Sulfate
- First Posted Date
- 2009-11-09
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 36
- Registration Number
- NCT01009892
- Locations
- 🇺🇸
CEDRA Clinical Research, San Antonio, Texas, United States
Pharmacokinetic and Comparative Bioavailability Study of Codeine Sulfate Under Fasted Conditions
- Conditions
- Pain
- First Posted Date
- 2009-11-09
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 18
- Registration Number
- NCT01010139
- Locations
- 🇺🇸
CEDRA Clinical Research, San Antonio, Texas, United States
Comparative Bioavailability Study of Codeine Sulfate
- First Posted Date
- 2009-11-09
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 34
- Registration Number
- NCT01010152
- Locations
- 🇺🇸
CEDRA Clinical Research LLC, San Antonio, Texas, United States
Steady State Study of Codeine Sulfate
- Conditions
- Pain
- First Posted Date
- 2009-11-09
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 34
- Registration Number
- NCT01009853
- Locations
- 🇺🇸
CEDRA Clinical Research, Austin, Texas, United States
Acute Pediatric Fracture Analgesia Study
- First Posted Date
- 2007-08-24
- Last Posted Date
- 2008-03-07
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 335
- Registration Number
- NCT00520442
- Locations
- 🇺🇸
Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
Assessment of Opioid Analgesia in Sickle Cell
- Conditions
- Sickle Cell Disease
- Interventions
- First Posted Date
- 2007-08-09
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Children's National Research Institute
- Registration Number
- NCT00513864
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway
- Conditions
- Depressive Disorder, MajorDiabetic NeuropathiesFibromyalgiaVasomotor Symptoms
- First Posted Date
- 2007-04-05
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT00456898
Double Blind Randomized Study Into the Efficacy of Codeine Phosphate Analgesia After Cleft Palate Repair in Infants
- Conditions
- Cleft Palate Repair
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2007-11-29
- Lead Sponsor
- Institute of Child Health
- Target Recruit Count
- 44
- Registration Number
- NCT00386269
- Locations
- 🇬🇧
Great Ormond Street Hospital, Anaesthetics, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.